Cargando…

The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective

BACKGROUND: Benchmark data on the population-level economic burden are critical to inform policymakers about liver cancer control. However, comprehensive data in China are currently limited. METHODS: A prevalence-based approach from a societal perspective was used to quantify the annual economic bur...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Meng-Di, Liu, Cheng-Cheng, Wang, Hong, Lei, Lin, Cao, Maomao, Wang, Yuting, Li, He, Yan, Xin-Xin, Li, Yan-Jie, Wang, Xin, Peng, Ji, Qu, Chunfeng, Feletto, Eleonora, Shi, Ju-Fang, Chen, Wanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308023/
https://www.ncbi.nlm.nih.gov/pubmed/35870941
http://dx.doi.org/10.1186/s12962-022-00370-3
_version_ 1784752896605159424
author Cao, Meng-Di
Liu, Cheng-Cheng
Wang, Hong
Lei, Lin
Cao, Maomao
Wang, Yuting
Li, He
Yan, Xin-Xin
Li, Yan-Jie
Wang, Xin
Peng, Ji
Qu, Chunfeng
Feletto, Eleonora
Shi, Ju-Fang
Chen, Wanqing
author_facet Cao, Meng-Di
Liu, Cheng-Cheng
Wang, Hong
Lei, Lin
Cao, Maomao
Wang, Yuting
Li, He
Yan, Xin-Xin
Li, Yan-Jie
Wang, Xin
Peng, Ji
Qu, Chunfeng
Feletto, Eleonora
Shi, Ju-Fang
Chen, Wanqing
author_sort Cao, Meng-Di
collection PubMed
description BACKGROUND: Benchmark data on the population-level economic burden are critical to inform policymakers about liver cancer control. However, comprehensive data in China are currently limited. METHODS: A prevalence-based approach from a societal perspective was used to quantify the annual economic burden of liver cancer in China from 2019 to 2030. Detailed per-case data on medical/non-medical expenditure and work-loss days were extracted from a multicenter survey. The numbers/rates of new/prevalent cases and deaths, survival, and population-related parameters were extracted from the Global Burden of Disease 2019 and the literature. All expenditure data were reported in both 2019 Chinese Yuan (CNY) and United States dollar (US$, for main estimations). RESULT: The overall economic burden of liver cancer was estimated at CNY76.7/US$11.1 billion in China in 2019 (0.047% of the local GDP). The direct expenditure was CNY21.6/US$3.1 billion, including CNY19.7/US$2.9 billion for medical expenditure and CNY1.9/US$0.3 billion for non-medical expenditure. The indirect cost was CNY55.1/US$8.0 billion (71.8% of the overall burden), including CNY3.0/US$0.4 billion due to disability and CNY52.0/US$7.5 billion due to premature death. The total burden would increase to CNY84.2/US$12.2 billion, CNY141.7/US$20.5 billion, and CNY234.3/US$34.0 billion in 2020, 2025, and 2030, accounting for 0.102%, 0.138%, and 0.192% of China's GDP, respectively. However, if China achieves the goals of Healthy China 2030 or the United Nations' Sustainable Development Goals for non-communicable diseases, the burden in 2030 would be < CNY144.4/US$20.9 billion. CONCLUSIONS: The population-level economic burden of liver cancer in China is currently substantial and will consistently increase in the future. Sustainable efforts in primary and secondary interventions for liver cancer need to be further strengthened. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12962-022-00370-3.
format Online
Article
Text
id pubmed-9308023
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93080232022-07-24 The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective Cao, Meng-Di Liu, Cheng-Cheng Wang, Hong Lei, Lin Cao, Maomao Wang, Yuting Li, He Yan, Xin-Xin Li, Yan-Jie Wang, Xin Peng, Ji Qu, Chunfeng Feletto, Eleonora Shi, Ju-Fang Chen, Wanqing Cost Eff Resour Alloc Research BACKGROUND: Benchmark data on the population-level economic burden are critical to inform policymakers about liver cancer control. However, comprehensive data in China are currently limited. METHODS: A prevalence-based approach from a societal perspective was used to quantify the annual economic burden of liver cancer in China from 2019 to 2030. Detailed per-case data on medical/non-medical expenditure and work-loss days were extracted from a multicenter survey. The numbers/rates of new/prevalent cases and deaths, survival, and population-related parameters were extracted from the Global Burden of Disease 2019 and the literature. All expenditure data were reported in both 2019 Chinese Yuan (CNY) and United States dollar (US$, for main estimations). RESULT: The overall economic burden of liver cancer was estimated at CNY76.7/US$11.1 billion in China in 2019 (0.047% of the local GDP). The direct expenditure was CNY21.6/US$3.1 billion, including CNY19.7/US$2.9 billion for medical expenditure and CNY1.9/US$0.3 billion for non-medical expenditure. The indirect cost was CNY55.1/US$8.0 billion (71.8% of the overall burden), including CNY3.0/US$0.4 billion due to disability and CNY52.0/US$7.5 billion due to premature death. The total burden would increase to CNY84.2/US$12.2 billion, CNY141.7/US$20.5 billion, and CNY234.3/US$34.0 billion in 2020, 2025, and 2030, accounting for 0.102%, 0.138%, and 0.192% of China's GDP, respectively. However, if China achieves the goals of Healthy China 2030 or the United Nations' Sustainable Development Goals for non-communicable diseases, the burden in 2030 would be < CNY144.4/US$20.9 billion. CONCLUSIONS: The population-level economic burden of liver cancer in China is currently substantial and will consistently increase in the future. Sustainable efforts in primary and secondary interventions for liver cancer need to be further strengthened. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12962-022-00370-3. BioMed Central 2022-07-23 /pmc/articles/PMC9308023/ /pubmed/35870941 http://dx.doi.org/10.1186/s12962-022-00370-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cao, Meng-Di
Liu, Cheng-Cheng
Wang, Hong
Lei, Lin
Cao, Maomao
Wang, Yuting
Li, He
Yan, Xin-Xin
Li, Yan-Jie
Wang, Xin
Peng, Ji
Qu, Chunfeng
Feletto, Eleonora
Shi, Ju-Fang
Chen, Wanqing
The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective
title The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective
title_full The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective
title_fullStr The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective
title_full_unstemmed The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective
title_short The population-level economic burden of liver cancer in China, 2019–2030: prevalence-based estimations from a societal perspective
title_sort population-level economic burden of liver cancer in china, 2019–2030: prevalence-based estimations from a societal perspective
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308023/
https://www.ncbi.nlm.nih.gov/pubmed/35870941
http://dx.doi.org/10.1186/s12962-022-00370-3
work_keys_str_mv AT caomengdi thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT liuchengcheng thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT wanghong thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT leilin thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT caomaomao thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT wangyuting thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT lihe thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT yanxinxin thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT liyanjie thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT wangxin thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT pengji thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT quchunfeng thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT felettoeleonora thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT shijufang thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT chenwanqing thepopulationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT caomengdi populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT liuchengcheng populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT wanghong populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT leilin populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT caomaomao populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT wangyuting populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT lihe populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT yanxinxin populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT liyanjie populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT wangxin populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT pengji populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT quchunfeng populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT felettoeleonora populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT shijufang populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective
AT chenwanqing populationleveleconomicburdenoflivercancerinchina20192030prevalencebasedestimationsfromasocietalperspective